$298.3 K

Nuo Therapeutics Revenue Q2, 2018
Nuo Therapeutics Net income (Q2, 2018)-1.3 M
Nuo Therapeutics EBIT (Q2, 2018)-1.3 M
Nuo Therapeutics Cash, 30-Jun-2018373.3 K

Nuo Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

11.6 m7.8 m11.5 m472.4 k

Revenue growth, %

(33%)48%(96%)

Cost of goods sold

8.4 m6.6 m

Gross profit

3.2 m1.2 m

Gross profit Margin, %

28%15%

Sales and marketing expense

6.2 m893.1 k

R&D expense

2.6 m1 m

General and administrative expense

6.8 m6 m9 m3.3 m

Operating expense total

6.8 m6 m17.8 m5.2 m

EBIT

(18.1 m)(23.4 m)(41.3 m)(5.5 m)

EBIT margin, %

(156%)(301%)(359%)(1155%)

Interest expense

1.7 m3.4 m3.8 m2.2 k

Pre tax profit

(20.2 m)(18.9 m)

Income tax expense

18.6 k19.6 k(89 k)

Net Income

(20.2 m)(18.9 m)(52.8 m)(5.7 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q2, 2018

Revenue

2.3 m1.7 m4.8 m2.9 m2.2 m1.4 m134.9 k176.8 k172.7 k162.2 k298.3 k

Cost of goods sold

1.9 m1.3 m

Gross profit

473.1 k401.6 k

Gross profit Margin, %

20%24%

Sales and marketing expense

1.8 m1.8 m1.6 m563.8 k237.3 k331.6 k213.7 k82.1 k

R&D expense

734.5 k597.8 k515.2 k375.2 k224.4 k323.5 k399.4 k398.1 k

General and administrative expense

1.3 m1.8 m2.8 m2.6 m2 m1.7 m602.8 k1.1 m974.4 k981.3 k

Operating expense total

1.3 m1.8 m5.4 m5 m4.1 m2.6 m1.1 m1.8 m1.6 m1.3 m1.5 m

EBIT

(9.8 m)(4.5 m)(3.4 m)(4.4 m)(27.3 m)(2 m)(1.1 m)(1.9 m)(1.7 m)(1.4 m)(1.3 m)

EBIT margin, %

(422%)(266%)(70%)(153%)(1257%)(140%)(820%)(1050%)(975%)(848%)(419%)

Interest expense

589.7 k818.5 k867 k912.6 k967 k206.2 k109 1.1 k6.6 k3.9 k367

Pre tax profit

(11.3 m)(4.8 m)(13.8 m)

Income tax expense

4.6 k4.6 k4.9 k4.9 k4.9 k

Net Income

(4.8 m)4.1 m(870.2 k)(13.8 m)(4.9 m)(1.3 m)(1.9 m)(1.7 m)(1.4 m)(1.3 m)

Nuo Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.3 m15.9 m922.3 k2.6 m

Inventories

1.3 m2.3 m804.5 k70 k

Current Assets

10 m21.9 m3 m3.4 m

PP&E

919.5 k925.2 k1.1 m486.1 k

Goodwill

1.1 m1.1 m2.1 m

Total Assets

46.3 m56.2 m7.1 m14.1 m

Accounts Payable

8 m1.9 m1.1 m392.6 k

Short-term debt

3.6 m

Current Liabilities

10.6 m8.5 m42.2 m1.4 m

Long-term debt

3.6 m

Total Debt

7.2 m

Total Liabilities

1.6 m

Common Stock

993

Preferred Stock

3

Additional Paid-in Capital

117.1 m125.2 m126 m18.2 m

Retained Earnings

(91.2 m)(110.1 m)(162.9 m)(5.7 m)

Total Equity

26.3 m15.5 m(36.6 m)12.5 m

Debt to Equity Ratio

0.3 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.8 x3.6 x-0.2 x1.1 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q2, 2018

Cash

25 m20 m11.8 m6.9 m4.1 m685.5 k6.1 m3.9 m1.3 m1.9 m373.3 k

Inventories

591.6 k544.7 k1 m717.1 k603.8 k158.6 k78.1 k48.2 k64.7 k367.5 k37.5 k

Current Assets

30.6 m25.7 m18.6 m12.8 m12.3 m3.1 m8.1 m5.6 m2.1 m2.6 m652.1 k

PP&E

706.4 k757.2 k999.1 k874.1 k865.1 k983.7 k787.3 k691.1 k388.4 k155.9 k

Goodwill

1.1 m1.1 m1.1 m1.1 m2.1 m2.1 m

Total Assets

65.3 m60.3 m52.7 m46.5 m19.2 m6.9 m19.6 m16.7 m12.4 m10.2 m823.3 k

Accounts Payable

8.4 m1.7 m2 m1.7 m2.5 m728.9 k1.3 m498.3 k378.3 k434.5 k523.5 k

Short-term debt

Current Liabilities

8.8 m7 m9 m7.9 m11.9 m2.6 m1.7 m1.5 m1.7 m1.1 m

Long-term debt

Total Liabilities

1.7 m1.1 m

Common Stock

993 993

Preferred Stock

3 3

Additional Paid-in Capital

123.4 m124.8 m125.5 m125.7 m125.8 m126 m18.1 m18.1 m18.2 m21.1 m21.7 m

Retained Earnings

(108.2 m)(113 m)(106 m)(106.9 m)(120.7 m)(167.8 m)(1.3 m)(3.2 m)(7.4 m)(12.7 m)(21.9 m)

Total Equity

15.6 m12.3 m19.9 m19.2 m5.5 m(41.4 m)16.8 m14.9 m10.8 m8.5 m(273.2 k)

Financial Leverage

4.2 x4.9 x2.6 x2.4 x3.5 x-0.2 x1.2 x1.1 x1.1 x1.2 x-3 x

Nuo Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(20.2 m)(18.9 m)(52.8 m)(5.7 m)

Depreciation and Amortization

1.1 m613.5 k741 k836.2 k

Inventories

(210.2 k)(1.1 m)272 k(21.6 k)

Accounts Payable

5.2 m(1.5 m)(811 k)(2.5 m)

Cash From Operating Activities

(11.4 m)(17.4 m)(14.4 m)(7.8 m)

Cash From Investing Activities

1.4 m(349.2 k)(629.4 k)100 k

Cash From Financing Activities

10.7 m30.4 m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q2, 2018

Net Income

(4.8 m)4.1 m(870.2 k)(13.8 m)(4.9 m)(1.3 m)(1.9 m)(1.7 m)(1.4 m)(1.3 m)

Depreciation and Amortization

51.8 k

Inventories

591.6 k544.7 k367.5 k(2.8 k)

Accounts Payable

8.4 m1.7 m2 m1.7 m2.5 m728.9 k1.3 m498.3 k378.3 k434.5 k143.2 k

Cash From Operating Activities

(822.2 k)

Cash From Investing Activities

2 k

Cash From Financing Activities

500 k

Nuo Therapeutics Ratios

USDY, 2018

Financial Leverage

-3 x
Report incorrect company information